Neisseria Gonorrhoeae

Most gonorrhea infections in women cause no symptoms at all. The infection can sit quietly in your genital tract for weeks or months, slowly raising your risk of pelvic inflammatory disease, infertility, ectopic pregnancy, and pregnancy complications, while you feel completely fine.

A vaginal swab test for NG (Neisseria gonorrhoeae) tells you whether the bacterium is currently present at the lower genital tract. It is the single most accurate way to catch the infection early enough to treat it before it climbs into the upper reproductive tract or gets passed to a partner.

What This Test Actually Measures

Unlike most lab tests, this one does not report a number on a scale. It looks for the genetic material of the gonorrhea bacterium itself, using a method called nucleic acid amplification testing (NAAT for short, a lab technique that copies and detects bacterial DNA or RNA). The result is simply positive or negative. A positive result means the bacterium is in your sample and you have an active infection. A negative result means no detectable infection at the time of collection.

Because this is a presence-versus-absence test, there is no concept of borderline, high, or optimal levels. There is infection, or there is not.

Why Vaginal Swabs Beat Urine and Cervical Samples

For decades, women were tested for gonorrhea using either a urine sample or a swab taken from the cervix during a pelvic exam. Newer evidence shows that a swab of the vaginal walls, which you can collect yourself, finds more infections than either of those alternatives.

In a meta-analysis of women tested with both methods, vaginal swabs detected 96.5% of gonorrhea infections compared with 90.7% for urine. An older study of young women entering the military, using an early-generation NAAT platform, found self-collected vaginal swabs picked up 72% of infections versus 40% from cervical swabs and only 24% from urine. Those numbers sit below the pooled estimates from more recent meta-analyses and reflect the assay and population of that single cohort, but the relative ranking of sample types is consistent. Editorial estimates suggest that defaulting to urine instead of vaginal swabs could miss more than 400,000 chlamydia and gonorrhea cases in the United States each year.

Source: Aaron et al. meta-analysis; Shafer et al. military cohort; Schachter et al. multicenter APTIMA evaluation; Krause et al. emergency department study.

What this means for you: if you are getting tested for gonorrhea, a vaginal swab gives you the most reliable answer. A negative urine test still leaves a meaningful chance of a missed infection. A negative vaginal swab leaves far less room for doubt.

Self-Collection Works as Well as a Doctor's Swab

A common concern is whether a self-collected swab is accurate enough. In a multicenter study using the APTIMA assay, self-collected and clinician-collected vaginal swabs had nearly identical performance, both around 96% sensitivity and over 99% specificity for gonorrhea. In an emergency department cohort, self-obtained vaginal swabs reached 95% sensitivity for combined gonorrhea and chlamydia detection, and 75% of patients preferred collecting their own swab over a pelvic exam.

You do not need a clinician to insert the swab to get a high-quality result. The bacterium sheds into vaginal secretions, so any properly collected swab of the vaginal walls will capture it if it is there.

What a Positive Result Actually Means

A positive vaginal swab means you currently have a gonorrhea infection in your genital tract. Most positive results come from people without symptoms. That asymptomatic window is exactly the problem: the infection has no obvious red flag, but it is still doing biological work.

Pelvic Inflammatory Disease and Fertility

Untreated genital gonorrhea can ascend from the cervix into the uterus and fallopian tubes, causing pelvic inflammatory disease. In a population-based cohort study of over 315,000 women, a gonorrhea infection was associated with a significantly higher risk of being hospitalized or treated in the emergency department for pelvic inflammatory disease. A systematic review and meta-analysis found that gonorrhea prevalence is several times higher in women being evaluated for infertility than in the general population, suggesting some infertility is preventable by detecting and treating gonorrhea early.

Pregnancy and Birth Outcomes

In a population-based cohort study in Washington State, maternal gonorrhea during pregnancy was associated with about 40% higher odds of having a low birth weight infant and about 60% higher odds of a small-for-gestational-age infant. A separate analysis of nearly 300,000 pregnancies found that gonorrhea raised the odds of preterm preeclampsia and preterm delivery. A meta-analysis of pregnancy outcomes linked gonorrhea to higher risks of preterm birth, premature rupture of membranes, perinatal death, low birth weight, and newborn eye infection.

In Botswana, screening and treating asymptomatic pregnant women using vaginal swabs cut the combined rate of preterm birth and low birth weight from 16% to 11%. The benefit was largest in women in their first pregnancy.

HIV Transmission Risk

Active gonorrhea infection enhances the transmission and acquisition of HIV. Inflammation at infected mucosal surfaces brings more immune cells to the area, giving HIV more targets to infect or more virus available to shed. Knowing your gonorrhea status is part of knowing your HIV risk.

Co-infections Are the Rule, Not the Exception

Gonorrhea rarely shows up alone. Studies consistently find high rates of co-detection with chlamydia, trichomonas, mycoplasma genitalium, and HPV on vaginal swabs. That is why modern testing platforms often run NG, chlamydia, and trichomonas as a triple panel from the same swab. A positive NG result should prompt a careful look at everything else that might be along for the ride, and a negative NG result alone does not clear you for other STIs.

When Results Can Be Misleading

Modern NAATs are highly accurate, but a few situations can mislead you. A small share of asymptomatic infections clear on their own. In one cohort, between visits about a week apart, roughly 23% of vaginal NG infections cleared without treatment. This means a positive followed by a quick negative is not necessarily a lab error. It can be real biological clearance, but it does not change the recommendation to treat any positive result you receive.

• Recent antibiotic use: if you have just finished antibiotics for another reason, residual treatment effect may temporarily suppress detection.
• Sample collection timing: very recent intercourse, douching, or use of vaginal products can occasionally affect sample quality, though NAATs are robust to most contamination.
• Lateral flow rapid tests: in mostly asymptomatic pregnant women, a rapid lateral flow gonorrhea test missed about one in three infections. If you used a rapid point-of-care test rather than a lab-based NAAT, a negative result is less reassuring.
• Site-limited infections: a vaginal swab catches genital infection. If exposure also involved the throat or rectum, those sites need separate swabs to be ruled out.

Why a Single Reading Is Not Enough

Gonorrhea testing is different from tracking a hormone or lipid. You are not building a trend line of a number that drifts over time. But repeat testing still matters, for three reasons.

First, reinfection is common. Treatment clears the current infection but offers no future immunity. If a partner is not also treated, or if you have new exposures, you can be reinfected within weeks. CDC guidelines recommend a retest about three months after treatment specifically to catch reinfection, not to confirm cure. Second, a true test of cure is not routinely needed for uncomplicated genital or rectal gonorrhea after standard treatment; it is recommended only for throat infections, performed 7 to 14 days after treatment, because pharyngeal infections are harder to eradicate. Third, even with negative results, regular screening catches the asymptomatic infections you would otherwise never know about.

A practical cadence for most sexually active women: baseline test now, retest about three months after any positive result to catch reinfection, and at least annually thereafter. Annual screening is recommended for sexually active women under 25 and for women 25 or older with risk factors such as new or multiple partners, an STI in the past year, or a partner with a known STI. Testing more often than once a year may make sense during periods of higher exposure risk or in pregnancy.

What to Do With an Out-of-Pattern Result

A positive vaginal swab for gonorrhea is not a watch-and-wait situation. It means active infection and calls for prompt treatment, partner notification, and a broader workup.

• Get treated quickly: the current CDC-recommended regimen is a single 500 mg intramuscular dose of ceftriaxone (1 g if you weigh 150 kg or more). If chlamydia has not been ruled out, doxycycline 100 mg twice daily for 7 days is added. Azithromycin is no longer co-recommended with ceftriaxone for gonorrhea. Treatment clears nearly all uncomplicated infections.
• Test for co-infections: order chlamydia, trichomonas, HIV, and syphilis at minimum. Co-infection is common, and treating gonorrhea alone leaves the others working in the background.
• Notify recent partners: any sexual partner from the past 60 days should be tested and treated. Without this step, you will likely be reinfected.
• Confirm cure only for throat infections: pharyngeal gonorrhea is the hardest site to eradicate and warrants a follow-up NAAT 7 to 14 days after treatment. For uncomplicated genital or rectal infections, a routine test of cure is not recommended after standard treatment.
• Retest at three months for reinfection: regardless of the treatment site, CDC guidelines recommend a repeat test about three months later to catch reinfection from a partner or new exposure.

If you are pregnant and test positive, treatment is urgent given the documented links to preterm birth, low birth weight, and newborn eye infections. The same ceftriaxone regimen is used and is safe in pregnancy.